Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XTNT Stock Forecast 2025-2026
$0.59
Current Price
$83.61M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XTNT Price Targets
+239.0%
To High Target of $2.00
+196.6%
To Median Target of $1.75
+154.2%
To Low Target of $1.50
XTNT Price Momentum
-4.8%
1 Week Change
-15.7%
1 Month Change
-15.7%
1 Year Change
+34.1%
Year-to-Date Change
-28.9%
From 52W High of $0.83
+78.8%
From 52W Low of $0.33
📊 TOP ANALYST CALLS
Did XTNT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xtant Medical is one of their latest high-conviction picks.
Latest XTNT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, XTNT has a bullish consensus with a median price target of $1.75 (ranging from $1.50 to $2.00). Currently trading at $0.59, the median forecast implies a 196.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ryan Zimmerman at BTIG, projecting a 239.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XTNT Analyst Ratings
2
Buy
0
Hold
0
Sell
XTNT Price Target Range
Low
$1.50
Average
$1.75
High
$2.00
Current: $0.59
Latest XTNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XTNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 16, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $3.00 |
| Dec 5, 2023 | BTIG | Ryan Zimmerman | Buy | Initiates | $2.00 |
| Jul 11, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $1.20 |
| Apr 26, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $1.00 |
| May 17, 2019 | Maxim Group | Hold | Downgrade | $0.00 | |
| Dec 8, 2016 | Maxim Group | Buy | Initiates | $0.00 | |
| Nov 30, 2016 | Aegis Capital | Buy | Initiates | $0.00 |
Xtant Medical Holdings Inc. (XTNT) Competitors
The following stocks are similar to Xtant Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
XTNT
Xtant Medical
mkt cap
86.73M
Xtant Medical Holdings Inc. (XTNT) Financial Data
Xtant Medical Holdings Inc. has a market capitalization of $83.61M with a P/E ratio of 75.1x. The company generates $122.30M in trailing twelve-month revenue with a -9.8% profit margin.
Revenue growth is +18.1% quarter-over-quarter, while maintaining an operating margin of +3.2% and return on equity of -26.2%.
Valuation Metrics
Market Cap
$83.61M
Enterprise Value
$112.87M
P/E Ratio
75.1x
PEG Ratio
-20.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+18.1%
Gross Margin
+61.5%
Operating Margin
+3.2%
Net Margin
-9.8%
EPS Growth
+18.0%
Financial Health
Cash/Price Ratio
+6.1%
Current Ratio
2.3x
Debt/Equity
78.2x
ROE
-26.2%
ROA
-5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xtant Medical Holdings Inc. (XTNT) Business Model
About Xtant Medical Holdings Inc.
What They Do
Develops regenerative medicine and surgical implants.
Business Model
Xtant Medical Holdings generates revenue by developing and selling regenerative medicine products and surgical implants primarily for orthopedic and neurological applications. The company targets hospitals, surgical centers, and clinics, providing innovative solutions that enhance patient outcomes and support the healing of complex injuries.
Additional Information
Xtant Medical is positioned as a key player in the medical technology sector, with its products playing a vital role in surgical interventions and recovery processes. The company's focus on biologics and advanced materials showcases its commitment to improving the quality of patient care and strengthening its market influence.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
217
CEO
Mr. Sean E. Browne
Country
United States
IPO Year
2015
Website
xtantmedical.comXtant Medical Holdings Inc. (XTNT) Latest News & Analysis
Latest News
Quick Summary
Xtant Medical Holdings, Inc. has launched OsteoFactor Pro™, an allogeneic growth factor solution aimed at enhancing bone healing in orthopedic and spine surgeries.
Why It Matters
The launch of OsteoFactor Pro™ positions Xtant Medical to capture market share in bone repair, potentially boosting revenue and enhancing investor confidence in the company's growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. (NYSE:XTNT) will hold its Q1 2025 earnings conference call on May 12, 2025, at 4:30 PM ET, featuring key executives and analysts.
Why It Matters
Xtant Medical's Q1 2025 earnings call signals key financial performance insights and strategic updates, influencing investor sentiment and potential stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings reported an 18% year-over-year revenue increase, positive net income, and $1.3 million in operating cash flow for Q1 2025. Revenue guidance for 2025 is now $127-$131 million.
Why It Matters
Xtant Medical's 18% revenue growth and positive cash flow signal strong financial health, while increased guidance for 2025 boosts confidence in future performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. (NYSE: XTNT) will release its Q1 2025 financial results on May 12, 2025, after market close.
Why It Matters
Xtant Medical's upcoming financial results could impact stock performance, reflecting company growth or challenges, influencing investor sentiment and decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. has launched Trivium™, a next-generation demineralized bone matrix allograft aimed at improving standards in bone grafting procedures.
Why It Matters
Xtant Medical's launch of Trivium™ enhances its product portfolio, potentially boosting revenue and market share in the growing orthopedic and spinal surgery sectors, influencing stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings completed a secondary sale of 73.1 million shares, led by Nantahala Capital Management, as part of a strategy to enhance its orthobiologics product offerings.
Why It Matters
The secondary share sale indicates strong institutional support and confidence in Xtant Medical's strategic shift to higher-margin products, potentially boosting investor sentiment and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XTNT Stock
What is Xtant Medical Holdings Inc.'s (XTNT) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Xtant Medical Holdings Inc. (XTNT) has a median price target of $1.75. The highest price target is $2.00 and the lowest is $1.50.
Is XTNT stock a good investment in 2025?
According to current analyst ratings, XTNT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XTNT stock?
Wall Street analysts predict XTNT stock could reach $1.75 in the next 12 months. This represents a 196.6% increase from the current price of $0.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xtant Medical Holdings Inc.'s business model?
Xtant Medical Holdings generates revenue by developing and selling regenerative medicine products and surgical implants primarily for orthopedic and neurological applications. The company targets hospitals, surgical centers, and clinics, providing innovative solutions that enhance patient outcomes and support the healing of complex injuries.
What is the highest forecasted price for XTNT Xtant Medical Holdings Inc.?
The highest price target for XTNT is $2.00 from Ryan Zimmerman at BTIG, which represents a 239.0% increase from the current price of $0.59.
What is the lowest forecasted price for XTNT Xtant Medical Holdings Inc.?
The lowest price target for XTNT is $1.50 from at , which represents a 154.2% increase from the current price of $0.59.
What is the overall XTNT consensus from analysts for Xtant Medical Holdings Inc.?
The overall analyst consensus for XTNT is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $1.75.
How accurate are XTNT stock price projections?
Stock price projections, including those for Xtant Medical Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:45 PM UTC